247
Participants
Start Date
April 1, 2023
Primary Completion Date
November 1, 2025
Study Completion Date
April 1, 2026
disease modifying treatments
Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
RECRUITING
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER